NCT02411448 2026-01-16RELAYEli Lilly and CompanyPhase 3 Active not recruiting545 enrolled 24 charts 2 FDA
NCT03292133 2025-06-10A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerMassachusetts General HospitalPhase 2 Terminated11 enrolled 10 charts
NCT00328562 2025-05-04ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerThomas Jefferson UniversityPhase 1 Completed13 enrolled 12 charts